Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC

Journal of Immunological Methods

Volumn 278, Issue 1-2, 2003, Pages 57-66

  Atanackovic, Djordje ^a   Matsuo, Mitsutoshi ^a   Ritter, Erika ^a   Mazzara, Gail ^b   Ritter, Gerd ^a   Jäger, Elke ^c   Knuth, Alexander ^c   Old, Lloyd J ^a   Gnjatic, Sacha ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b Therion Biologics Corporation   (United States)

^c KRANKENHAUS NORDWEST   (Germany)

Author keywords

Antigen presentation and processing; CD4+ T cell; Immuno monitoring; Viral and tumor antigen

Indexed keywords

EPITOPE; GAMMA INTERFERON; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NUCLEOPROTEIN; PEPTIDE; TUMOR ANTIGEN; VIRUS ANTIGEN; VIRUS PROTEIN; VIRUS VECTOR;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; EXPRESSION VECTOR; FOWLPOX VIRUS; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOLOGICAL TECHNIQUE; IMMUNOSTIMULATION; MEMORY CELL; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; T LYMPHOCYTE;

EID: 0142039245     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(03)00209-6     Document Type: Article

References (28)

1. Banchereau J., Palucka A.K., Dhodapkar M., Burkeholder S., Taquet N., Rolland A., Taquet S., Coquery S., Wittkowski K.M., Bhardwaj N., Pineiro L., Steinman R., Fay J. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61:2001;6451-6458.
2. Barnaba V., Watts C., de Boer M., Lane P., Lanzavecchia A. Professional presentation of antigen by activated human T cells. Eur. J. Immunol. 24:1994;71-75.
3. Brett S.J., Blau J., Hughes-Jenkins C.M., Rhodes J., Liew F.Y., Tite J.P. Human T cell recognition of influenza A nucleoprotein. Specificity and genetic restriction of immunodominant T helper cell epitopes. J. Immunol. 147:1991;984-991.
4. Chaux P., Vantomme V., Stroobant V., Thielemans K., Corthals J., Luiten R., Eggermont A.M., Boon T., van der Bruggen P. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J. Exp. Med. 189:1999;767-778.
5. Dhodapkar M.V., Steinman R.M., Sapp M., Desai H., Fossella C., Krasovsky J., Donahoe S.M., Dunbar P.R., Cerundolo V., Nixon D.F., Bhardwaj N. Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. J. Clin. Invest. 104:1999;173-180.
6. Dunbar P.R., Ogg G.S., Chen J., Rust N., van der Bruggen P., Cerundolo V. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood. Curr. Biol. 8:1998;413-416.
7. Fast L.D. Recipient elimination of allogeneic lymphoid cells: donor CD4(+) cells are effective alloantigen-presenting cells. Blood. 96:2000;1144-1149.
8. Franco A., Paroli M., Testa U., Benvenuto R., Peschle C., Balsano F., Barnaba V. Transferrin receptor mediates uptake and presentation of hepatitis B envelope antigen by T lymphocytes. J. Exp. Med. 175:1992;1195-1205.
9. Gnjatic S., Nagata Y., Jager E., Stockert E., Shankara S., Roberts B.L., Mazzara G.P., Lee S.Y., Dunbar P.R., Dupont B., Cerundolo V., Ritter G., Chen Y.T., Knuth A., Old L.J. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc. Natl. Acad. Sci. U. S. A. 97:2000;10917-10922.
10. Greten T.F., Jaffee E.M. Cancer vaccines. J. Clin. Oncol. 7:1999;1047-1060.
11. Hural J.A., Friedman R.S., McNabb A., Steen S.S., Henderson R.A., Kalos M. Identification of naturally processed CD4 T cell epitopes from the prostate-specific antigen kallikrein 4 using peptide-based in vitro stimulation. J. Immunol. 169:2002;557-565.
12. + T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc. Natl. Acad. Sci. U. S. A. 97:2000;12198-12203.
13. Jager E., Jager D., Karbach J., Chen Y.T., Ritter G., Nagata Y., Gnjatic S., Stockert E., Arand M., Old L.J., Knuth A. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4* 0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J. Exp. Med. 191:2000;625-630.
14. Jäger E., Nagata Y., Gnjatic S., Wada H., Stockert E., Karbach J., Dunbar P.R., Lee S.Y., Jungbluth A., Jäger D., Arand M., Ritter G., Cerundolo V., Dupont B., Chen Y.-T., Old L.J., Knuth A. Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses. Proc. Natl. Acad. Sci. U. S. A. 97:2000;4760-4765.
15. Keene J.A., Forman J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155:1982;768-782.
16. Lanzavecchia A., Roosnek E., Gregory T., Berman P., Abrignani S. T cells can present antigens such as HIV gp120 targeted to their own surface molecules. Nature. 334:1988;530-532.
17. LaSalle J.M., Ota K., Hafler D.A. Presentation of autoantigen by human T cells. J. Immunol. 147:1991;774-780.
18. + cytotoxic T-cell responses during chronic viral infection. J. Virol. 68:1994;8056-8063.
19. Messi M., Giacchetto I., Nagata K., Lanzavecchia A., Natoli G., Sallusto F. Memory and flexibility of cytokine gene expression as separable properties of human T(H)1 and T(H)2 lymphocytes. Nat. Immunol. 4:2003;78-86.
20. Novak E.J., Liu A.W., Nepom G.T., Kwok W.W. MHC class II tetramers identify peptide-specific human CD4(+) T cells proliferating in response to influenza A antigen. J. Clin. Invest. 104:1999;R63-R67.
21. Pathan A.A., Wilkinson K.A., Klenerman P., McShane H., Davidson R.N., Pasvol G., Hill A.V., Lalvani A. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J. Immunol. 167:2001;5217-5225.
22. Pichler W.J., Wyss-Coray T. T cells as antigen-presenting cells. Immunol. Today. 15:1994;312-315.
23. Salgado F.J., Lojo J., Fernandez-Alonso C.M., Vinuela J., Cordero O.J., Nogueira M. Interleukin-dependent modulation of HLA-DR expression on CD4 and CD8 activated T cells. Immunol. Cell Biol. 80:2002;138-147.
24. Schuler-Thurner B., Schultz E.S., Berger T.G., Weinlich G., Ebner S., Woerl P., Bender A., Feuerstein B., Fritsch P.O., Romani N., Schuler G. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195:2002;1279-1288.
25. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., Schreiber R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 410:2001;1107-1111.
26. Yang J., Lemas V.M., Flinn I.W., Krone C., Ambinder R.F. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens. Blood. 95:2000;241-248.
27. + T cells. Cancer Res. 62:2002;213-218.
28. + T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J. Immunol. 165:2000;1153-1159.